Merrimack Phase 3 Results Press Release

FOR IMMEDIATE RELEASE

NEW CHEMOTHERAPY COMBINATION EXTENDS SURVIVAL FOR
METASTATIC PANCREATIC CANCER BY NEARLY TWO MONTHS

MM-398 in Combination with 5-FU and Leucovorin Provides New Treatment Option for
Patients Previously Treated with Gemcitabine

MANHATTAN BEACH, CA (May 1, 2014) – The Pancreatic Cancer Action Network is pleased to announce that today Merrimack Pharmaceuticals, Inc., (Merrimack) reported a 1.9 month improvement in survival for patients treated with the combination of its drug, MM-398, with 5-fluorouracil (5-FU) and leucovorin. According to Merrimack, the NAPOLI-1 phase III study achieved an overall survival of 6.1 months, compared to 4.2 month survival demonstrated by the control group of 5-FU and leucovorin. The study involved three participant groups, all patients with metastatic pancreatic cancer who had been previously treated with gemcitabine (Gemzar®) -based chemotherapy. Patients were treated with either Merrimack’s drug, MM-398 (irinotecan liposome injection), the chemotherapy drug 5-FU and leucovorin (a standard treatment option) or a combination of MM-398 with 5-FU and leucovorin.

The results of this trial are encouraging for pancreatic cancer patients, a disease where many patients need to pursue several options during the course of treatment. Approximately 55 percent of pancreatic cancer patients are diagnosed with metastatic disease, and most who are diagnosed at an earlier stage eventually progress to this stage. This treatment has the potential to be an option for many patients where to date, little therapeutic progress has been made. The success of this trial highlights the importance of designing trials that explore options beyond first-line therapy.

“The Pancreatic Cancer Action Network’s goal is to double pancreatic cancer survival by 2020. The positive results of this trial demonstrate progress toward that goal in a disease for which additional treatment options are urgently needed to improve patient outcomes,” stated Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “Though we always hope for momentous solutions to treat pancreatic cancer, we are encouraged by any type of progress. We know any new developments will eventually lead to even greater treatment advances, and also underscore the important role clinical trials play when patients are exploring their treatment options. We applaud Merrimack’s dedication to improving the treatment landscape for this patient population, and helping us charge forward in the fight against pancreatic cancer.”

The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. The organization has a comprehensive up-to-date database of all approved pancreatic cancer-specific clinical trials taking place nationwide and can do a personalized search for patients through our Patient and Liaison Services (PALS) program.

“As a result of this specific trial, 417 patients have helped change treatment options for this disease and created a legacy of progress to those yet to be diagnosed,” added Fleshman.

Pancreatic cancer is one of the nation’s deadliest cancers with a five-year survival rate of just 6 percent. It is currently the fourth leading cause of cancer death in the United States, and is anticipated to become the second by 2020. This year, an estimated 46,000 American’s will be diagnosed with the disease and nearly 40,000 will die.

For more information about the Pancreatic Cancer Action Network and clinical trials visit www.pancan.org. Find us on Twitter @PanCAN and on Facebook www.facebook.com/jointhefight.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

###

Contact:

Jennifer Rosen
Senior Manager, Public Relations
Pancreatic Cancer Action Network
Direct: 310-706-3362
Email: jrosen@pancan.org

ALL OTHER INQUIRIES, PLEASE CALL THE PANCREATIC CANCER ACTION NETWORK AT 877-272-6226 OR EMAIL INFO@PANCAN.ORG.

FOR questions about clinical trials, or for personalized clinical trials searches, email  PALS@pancan.org, or call 877-272-6226, Monday – Friday, 7 a.m. – 5 p.m., PT.